Skip to main content
49°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Exscientia plc
Exscientia Business and Financial Update for the Full Year 2023
March 21, 2024
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Report Full Year 2023 Financial Results on March 21, 2024
March 14, 2024
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present at Upcoming Investor Conferences in March
February 28, 2024
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients
February 07, 2024
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme
December 21, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
December 05, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business Update for Third Quarter 2023
November 09, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Report Third Quarter 2023 Financial Results on November 9, 2023
November 02, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Parker Moss to Join Exscientia as EVP, Corporate Development
October 17, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023
October 16, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Details Pipeline Prioritisation Strategy
October 03, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
September 20, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present at Upcoming Investor Conferences in September
August 31, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business Update for Second Quarter and First Half of 2023
August 10, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours
July 10, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business Update for First Quarter 2023
May 24, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe
May 22, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023
May 17, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
May 15, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors
May 03, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development
April 19, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Report Full Year 2022 Financial Results on March 23, 2023
March 16, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR
March 15, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces Expansion of its Precision Oncology Pipeline
March 14, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform
March 07, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present at Upcoming Investor Conferences in March
February 22, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
February 02, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress
December 06, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.